On February 4, the first Jinrong Pharmaceutical Patent Salon & In Vitro Diagnostic Reagent Patent Protection Seminar, jointly organized by Boercheng (Beijing) Technology Co., Ltd., Beijing Modern Gaoda Biotechnology Co., Ltd., Beijing Caihe Law Firm, and Beijing Tangsong Yongxin Intellectual Property Agency Co., Ltd., was successfully held on the 10th floor of the main building at No. 18 Hongda South Road, Beijing Economic‑Technological Development Area.
At the event, Mr. James Wang, Chairman of Boercheng (Beijing) Technology Co., Ltd., gave a presentation on the rapid development of the in vitro diagnostic reagent industry. This was followed by a keynote lecture delivered by Attorney Yansangtian, a partner at Beijing Caihe Law Firm, titled “Patent Application and Protection in the Field of In Vitro Diagnostic Reagents.” The lecture covered topics such as patent landscape surveys, patent examination practices, and litigation and enforcement strategies in the IVD reagent sector.During the salon, participants from Modern Gaoda and BOE also took part in the Q&A session and discussion.
About Boercheng (Beijing) Technology Co., Ltd.
Founded in 2006 in Beijing Zhongguancun, Boercheng (Beijing) Technology Co., Ltd. focuses on the industrialization of early‑diagnosis products for major diseases such as cancer. It is one of the pioneers and leaders in China capable of realizing the entire industrial chain for early cancer detection and early intervention.Its overseas affiliate, BioChain Institute, Inc., was established in 1994 in Silicon Valley, USA, and is an international supplier of biological sample processing and R&D products, with distribution agents in 48 countries and regions.Boercheng is a high‑tech enterprise integrating in vitro diagnostic products and biological reagents R&D, manufacturing, and sales, biomedical translation, and clinical medical testing services. The company possesses strong development capabilities in areas such as tumor gene methylation, tumor‑specific biomarkers, liquid biopsy, and fully automated sample processing instruments. It independently completes the entire process — from core raw material development, discovery and clinical validation of tumor biomarkers, to product registration and industrialization.
